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Spinobulbar muscular atrophy (SBMA) is a neurode-
generative disease caused by expansion of a poly-
glutamine tract in the androgen receptor (AR). This
mutation confers toxic function to AR through
unknown mechanisms. Mutant AR toxicity requires
binding of its hormone ligand, suggesting that path-
ogenesis involves ligand-induced changes in AR.
However, whether toxicity is mediated by native AR
function or a novel AR function is unknown. We
systematically investigated events downstream of
ligand-dependent AR activation in a Drosophila
model of SBMA. We show that nuclear translocation
of AR is necessary, but not sufficient, for toxicity and
that DNA binding by AR is necessary for toxicity.
Mutagenesis studies demonstrated that a functional
AF-2 domain is essential for toxicity, a finding
corroborated by a genetic screen that identified
AF-2 interactors as dominant modifiers of degenera-
tion. These findings indicate that SBMA pathogen-
esis is mediated by misappropriation of native
protein function, a mechanism that may apply
broadly to polyglutamine diseases.
INTRODUCTION
Spinobulbar muscular atrophy (SBMA, also known as Kennedy’s
disease) is a progressive late-onset degenerative disorder of the
motor neurons in the brainstem and spinal cord that affects only
men (Kennedy et al., 1968). SBMA is a member of the polyglut-
amine repeat disease family, which includes at least eight other
disorders, including Huntington’s disease (HD), dentatorubral-
pallidoluysian atrophy (DRPLA), and six forms of spinocerebellar936 Neuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc.ataxia (SCA). All of these diseases are caused by gain-of-func-
tion mutations characterized by expanded trinucleotide (CAG)
repeats in exonic regions of DNA, and all result in late-onset,
progressive neurodegeneration (Zoghbi and Orr, 2000).
In SBMA, the CAG repeat site is located in the androgen receptor
(AR) gene and causes disease when the number of repeats is 40
or greater (La Spada et al., 1991). Patients often display signs of
mild feminization, likely due to partial loss of AR function.
Although loss of AR function may contribute to disease (Thomas
et al., 2006), it is not sufficient for degeneration, as loss-of-func-
tion mutations to AR result in androgen insensitivity syndrome
without signs of neuronal degeneration (Quigley et al., 1992).
A central mystery in the field of polyglutamine disease
research arises from the observation that the same mutation in
nine different proteins results in nine different diseases; yet in
each disease, different subsets of neurons are affected. This
pattern occurs despite widespread and overlapping expression
of the disease proteins, suggesting that the inherent toxicity of
the expanded polyglutamine is not the sole basis of toxicity.
Indeed, in SBMA mouse models, expression of polyglutamine-
expanded fragments of AR results in widespread neuronal
degeneration, a phenotype that is not dissimilar from that
observed in transgenic animal models expressing fragments of
other polyglutamine-expanded proteins (Abel et al., 2001). In
contrast, models employing full-length polyglutamine-expanded
AR protein more accurately reflect the human disease, display-
ing restricted symptoms, lower motor neuron specificity in
degeneration, and gender specificity (Chevalier-Larsen et al.,
2004; Sopher et al., 2004).
These findings highlight the importance of protein context in
polyglutamine disease, and raise the question of the role of
protein domains other than the polyglutamine tract in toxicity.
It is not clear whether the mutation results in the formation of
novel, toxic interactions, or whether the mutation alters the
normal, native interactions of the polyglutamine-containing
protein in such a way as to result in neurotoxicity. Though these
possibilities are not mutually exclusive, recent studies in SCA1,
Neuron
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which the normal function of the disease protein is tied to the
mechanism of pathogenesis (Emamian et al., 2003; Friedman
et al., 2007; Helmlinger et al., 2006; Lim et al., 2008; McMahon
et al., 2005; Palhan et al., 2005; Tsuda et al., 2005). More direct
evidence that native interactions may mediate toxicity comes
from animal models in which overexpression of nonexpanded
ataxin-1 or AR results in pathology resembling SCA1 and
SBMA, respectively (Fernandez-Funez et al., 2000; Monks
et al., 2007).
In the majority of polyglutamine diseases, neither the primary
function nor the native interactors of the disease proteins are
well known. SBMA is an exception in that the disease protein
has a well-characterized role as a ligand-dependent transcrip-
tion factor. AR is a member of the nuclear hormone receptor
(NHR) superfamily and resides in the cytoplasm when inactive.
A number of events occur upon ligand binding, the final result
of which is AR-mediated activation or repression of target genes.
These ligand-induced events include several posttranslational
modifications, nuclear translocation, and DNA binding. These
changes occur in concert with conformational changes that
result in the exposure of two coregulator interaction surfaces,
termed activation function-1 (AF-1) and activation function-2
(AF-2). Ligand binding to polyglutamine-expanded AR is a requi-
site step in disease pathogenesis. Indeed, there is now incontro-
vertible evidence from animal model studies as well as human
studies that gender specificity in SBMA is due to higher levels
of circulating androgens in males (Katsuno et al., 2002; Take-
yama et al., 2002).
Although the basis of the toxic gain of function imparted by the
polyglutamine expansion remains unknown, the ligand depen-
dence of SBMA implies that ligand-induced alterations of AR
play important roles in toxicity. In this study, we used
a Drosophila model to test the hypothesis that SBMA is medi-
ated by ligand-induced alterations in native AR interactions.
First, we present evidence that nuclear translocation of AR is
necessary, but not sufficient, for toxicity, demonstrating that
ligand-induced modifications of AR (beyond nuclear transloca-
tion) are required for pathogenesis. Second, we show that
DNA binding of polyglutamine-expanded AR is required for
toxicity, indicating that the native DNA-binding function of AR
is critical to pathogenesis. Third, we use a genetic screen to
identify modifiers of SBMA toxicity, which reveal a pattern of
AF-2-based coregulators that genetically interact with polyglut-
amine-expanded AR. Pursuing this finding, we show rescue of
polyglutamine-expanded AR toxicity through two independent
point mutations designed to disrupt the AF-2 coregulator inter-
action surface. To more precisely define the degenerative
phenotype associated with polyglutamine-expanded AR
toxicity, we used expression profile analysis. This analysis
confirmed that interruption of either the AF-2 or DNA binding
domains robustly suppressed this molecular phenotype. In addi-
tion, analysis of the molecular phenotype of flies expressing
wild-type AR revealed the same (albeit weaker) molecular
phenotype as polyglutamine-expanded AR, indicating that
amplification of normal AR function may underlie the toxicity of
polyglutamine-expanded AR. Finally, we investigated the AR
coregulator ortholog limpet, a gene identified in our geneticscreen, as proof of principle that polyglutamine-expanded AR
toxicity is mediated via native function of the AF-2 binding
surface following DNA binding.
RESULTS
Expression of Polyglutamine-Expanded AR
in Drosophila Results in Toxicity
In order to investigate the contributions of AR interactions to
polyglutamine-expanded AR toxicity, we used a Drosophila
model of SBMA. Although human AR has no direct ortholog in
flies, the NHR system is well conserved (King-Jones and
Thummel, 2005). This conservation is reflected in the domain
architecture of Drosophila nuclear receptors, including AF-1
and AF-2 coregulator interaction domains that bind to conserved
motifs in nuclear receptor coregulators. It was previously
demonstrated that human AR expressed in Drosophila tissues
translocates to the nucleus and activates transcription of an
ARE-GFP reporter transgene in response to dihydrotestosterone
(DHT) (Takeyama et al., 2002). This cross-species transactiva-
tional capacity reflects the fact that human AR interacts with
endogenous Drosophila coactivators and corepressors; indeed,
genetic modulation of Drosophila homologs of mammalian AR
coregulators can modify the transactivational capacity of AR
in vivo (Takeyama et al., 2004).
When human AR of varying polyglutamine lengths is
expressed using the GAL4-UAS system (Brand and Perrimon,
1993), flies develop polyglutamine length- and ligand-dependent
degenerative phenotypes, thus recapitulating two fundamental
features of SBMA (Pandey et al., 2007; Takeyama et al., 2002).
To assess toxicity in an externally visible neuronal tissue, we
expressed AR in the eye using the glass multimer reporter driver
(GMR-GAL4), which leads to transgene expression in photore-
ceptor neurons and accessory pigment cells in developing eye
discs (Moses and Rubin, 1991). Whereas flies expressing AR
show no eye phenotypewhen reared on normal food, flies reared
on food containing DHT exhibit a degenerative phenotype that is
limited to the posterior margin of the eye (Figure 1A). The severity
of the phenotype is also polyglutamine-length dependent, with
AR52Q-expressing flies showing severe ommatidial pitting,
disorganization, and fusion, as well as abnormal and supernu-
merary interommatidial bristles. In contrast, AR12Q-expressing
flies show only mild ommatidial and bristle phenotypes when
the transgene is expressed at equivalent levels (Figures
1A–1C). Confocal imaging of eye discs confirmed that AR
undergoes DHT-dependent nuclear translocation in vivo. This
analysis also revealed diffuse nuclear accumulation of AR and
the formation of small nuclear and cytoplasmic puncta that
were particularly prominent with polyglutamine-expanded AR
(Figure 1D).
The polyglutamine length- and DHT-dependence of SBMA is
recapitulated in several larval tissues. For example, using the
larval salivary gland driver (fkh-GAL4) (Andrew et al., 2000),
expression of polyglutamine-expanded AR results in a dramatic
reduction of salivary gland cell size (Figures 1E and 1F). Larvae
expressing AR in motor neurons under the control of the D42-
GAL4 driver (Yeh et al., 1995) also show polyglutamine length-
and DHT-dependent defects in locomotor ability as measuredNeuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc. 937
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Figure 1. Expression of Polyglutamine-Expanded AR in Drosophila Results in Toxicity
(A) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing vehicle or DHT and adult eye phenotypes were assessed
by light microscopy.
(B) Blinded scoring of the external eye phenotypes in (A) using a quantitative scoring system (Pandey et al., 2007).
(C) Western blot showing levels of AR expression for AR12Q- and AR52Q-expressing flies shown in (A).
(D) Pupae expressing AR in eyes using GMR-GAL4 were raised in medium with or without DHT and whole-mount preparations of eye discs were immunostained
for lamin (blue) and AR (green). Phalloidin (red) was used to stain F-actin. Samples were examined by confocal microscopy.
(E and F) Third instar larvae expressing AR in the salivary gland using fkh-GAL4were dissected and stained with DAPI (blue) and phalloidin (red). Overall gland size
is shown in (E), and cell size is shown in (F). Phalloidin staining was used to delineate cell boundaries and determine cell size. Scale bar, 50 mm.
(G) Third instar larvae expressing AR12Q or AR52Q using D42-GAL4 were assessed for their ability to travel distances along the surface of an agar plate.
(H and I) Larvae expressing AR52Q using OK371-GAL4 were raised in medium containing vehicle or DHT, dissected as third instar wandering larvae, and stained
using the postsynaptic marker discs large (DLG, green) and the presynaptic marker HRP (red). Type 1B boutons were counted at muscle 4. Scale bar, 10 mm.
(J) Female flies expressing AR12Q using GMR-GAL4 were raised on medium containing DHT. Each line shown represents an independent transformant line.
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Native Functions of AR Mediate SBMA Pathogenesisby larval crawling assay, indicating a significant functional deficit
(Figure 1G). In addition, the number of type 1B boutons at the
larval neuromuscular junction (NMJ) is significantly decreased
in a DHT-dependent manner when polyglutamine-expanded
AR is expressed using the motor neuron driver OK371-GAL4
(Mahr and Aberle, 2006) (Figures 1H and 1I).
Importantly, we noticed that expression of wild-type polyglut-
amine-length AR at high levels results in a degenerative
phenotype that is indistinguishable from that caused by polyglut-
amine-expanded AR (Figures 1J and 1K). This is reminiscent of
the SBMA-like phenotype associated with high-level expression
of wild-type AR in mice (Monks et al., 2007). The dose-depen-
dent toxicity of wild-type AR suggests the possibility that ampli-
fication of native AR function may contribute to the toxicity of
polyglutamine-expanded AR.
Nuclear Translocation of Polyglutamine-Expanded AR
Is Necessary for Toxicity
The observation that ligand binding to AR is required for patho-
genesis suggests a model in which nontoxic AR is converted
to a proteotoxin through ligand-induced events. The first major
event to occur upon ligand binding is translocation of AR to the
nucleus. In most polyglutamine diseases, the primary site of
cellular toxicity is thought to be the nucleus (Klement et al.,
1998; Montie et al., 2009; Peters et al., 1999; Saudou et al.,
1998; Takeyama et al., 2002), although cytoplasmic toxicity
may also contribute (Hodgson et al., 1999; Morfini et al., 2006;
Szebenyi et al., 2003). In the case of SBMA, whether nuclear
translocation of polyglutamine-expanded AR is both necessary
and sufficient for toxicity has not been examined in vivo.
AR has three major domains (Figure 2A): (1) an N-terminal
transactivation domain (NTD) that contains AF-1 and serves
as a coregulator interaction surface, (2) a DNA-binding domain
(DBD) that binds regulatory elements in AR-regulated pro-
moters, and (3) a C-terminal ligand-binding domain (LBD) that
binds testosterone or DHT and also harbors a second cor-
egulator interaction surface (AF-2). Bridging the DBD and LBD
is a flexible hinge domain that harbors a bipartite nuclear local-
ization sequence (NLS). To address the necessity of nuclear
translocation, we generated two AR constructs designed to
remain in the cytoplasm even in the presence of DHT
(Figure 2A). In the first construct, we used phosphomimetic
substitutions of serines 210 and 790 (AR65Q SS/DD) that
prevent DHT binding to AR (Palazzolo et al., 2007). In the
second construct, we mutated residues K632 and K633
(AR73Q KK/AA) in the NLS of AR; these substitutions markedly
alter DHT-induced nuclear translocation (Thomas et al., 2004).
COS-1 cells transfected with these constructs showed that
the SS/DD and KK/AA mutations each caused AR to remain
in the cytoplasm even in the presence of DHT (Figures S1A
and S1B available online).
In order to investigate whether these cytoplasmic AR mutants
cause toxicity in vivo, we generated transgenic Drosophila lines(K) Western blot analysis of heads shown in (J).
In (A) and (J), left side of each diptych shows lightmicrograph imaged at 633, while
eye in which degeneration is concentrated. **p < 0.01 in all panels. Bars, mean +that express these proteins under the control of the GAL4-UAS
system.We first confirmed that thesemodified AR proteins resist
DHT-induced nuclear translocation in vivo in Drosophila by
expressing the AR transgeneswith the larval salivary gland driver
fkh-GAL4. Salivary glands provide an ideal model to assess
subcellular localization of proteins in Drosophila due to their
highly ordered histoarchitecture and high ratio of cytoplasm to
nucleus. Using fkh-GAL4, we found that whereas AR52Q
showed nuclear localization, AR65Q SS/DD and AR73Q KK/AA
remained in the cytoplasm despite the presence of DHT in the
larval medium (Figure 2C).
In order to test the toxicity of these constructs in a neuronal
tissue, we next expressed the AR transgenes using GMR-GAL4.
As previously shown, expression of AR52Q in the eye resulted in
a degenerative phenotype in a DHT-dependent manner (Figures
2B and 2D). In contrast, eyes expressing AR65Q SS/DD or
AR73Q KK/AA showed no degenerative phenotype even in the
presence of DHT, despite high expression of AR (Figures 2B,
2D, and S2A). Consistent with prior reports (Montie et al.,
2009; Takeyama et al., 2002), these results indicate that nuclear
translocation of polyglutamine-expanded AR is necessary for
toxicity.
Nuclear Translocation of Polyglutamine-Expanded AR
Is Not Sufficient for Toxicity
In order to address whether nuclear translocation of polyglut-
amine-expanded AR is sufficient for toxicity, we designed AR
constructs that translocate to the nucleus in a DHT-independent
manner, thereby dissociating nuclear translocation from ligand
binding. To this end, we fused the SV40 NLS to either the C or
N terminus of AR (Figure 2A). As an additional control, we fused
an NLS to the AR65Q SS/DD protein that is unable to bind DHT.
COS-1 cells transfectedwith AR65Q-NLS or NLS-AR65QSS/DD
show AR localized to the nucleus even in the absence of DHT
(Figures S1C and S1D). In addition, AR65Q-NLS retained its
transactivation ability in response to DHT as measured by an
ARE-luciferase reporter, though only at about 50% of AR65Q
(Figure S1E). As expected, NLS-AR65Q SS/DD did not activate
transcription, due to its inability to bind DHT.
We next made transgenic Drosophila carrying UAS-AR65Q-
NLS and UAS-NLS-AR65Q SS/DD. After confirming that
AR65Q-NLS and NLS-AR65Q SS/DD translocate to the nucleus
in the absence of DHT in vivo using fkh-GAL4 (Figure 2E), we
expressed these transgenes in the eye using GMR-GAL4
(Figures 2F and S2B). Expression of AR65Q-NLS or NLS-
AR65Q SS/DD did not cause toxicity in the absence of DHT,
indicating that nuclear translocation of polyglutamine-expanded
AR is not sufficient for toxicity. However, once the AR65Q-NLS
animals were exposed to DHT, they developed the characteristic
SBMA eye phenotype, demonstrating that DHT binding to AR
provides the critical step in the conversion of polyglutamine-
expanded AR from a nontoxic to a toxic molecule (Figures
2B and 2F).right side shows increasedmagnification (1403) of the posterior region of the
SEM in all panels.
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Figure 2. Nuclear Localization of Polyglutamine-Expanded AR Is Necessary, but Not Sufficient, for Toxicity In Vivo
(A) Schematic of AR constructs used. NTD, N-terminal transactivation domain; DBD, DNA-binding domain; H, hinge; LBD, ligand-binding domain; NLS, nuclear
localization sequence. (B) Blinded scoring of the external eye phenotypes in (D) and (F) using a quantitative scoring system. Bars, mean + SEM. (C) Salivary glands
of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and processed for immunocytochemistry. AR was detected
with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 mm. (D) Drosophila females expressing AR in eyes using GMR-GAL4 were
raised inmedium containing vehicle or DHT and adult eye phenotypes were assessed by light microscopy. (E) Salivary glands ofDrosophila larvae expressing AR
using fkh-GAL4. Larvae were raised in medium containing ethanol and processed for immunocytochemistry as in (C). Scale bar, 50 mm. (F) Drosophila females
expressing AR in eyes usingGMR-GAL4were raised inmedium containing vehicle or DHT and adult eye phenotypeswere assessed by light microscopy. See also
Figures S1 and S2.
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for Polyglutamine-Expanded AR Toxicity
Having determined that the role of DHT in SBMA is not simply to
effect translocation of AR to the nuclear compartment, but also
to modify nuclear AR, we hypothesized that AR’s function as a
DNA-binding transcription factor might play a role in pathogen-
esis. To investigate this hypothesis, we introduced a mutation
to the AR DBD (A574D) that blocks the ability of AR to bind940 Neuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc.DNA without disrupting its ligand-binding ability (Bru¨ggenwirth
et al., 1998).
AR65Q A574D showed normal DHT-induced nuclear translo-
cation in vitro (Figure S3), although transactivation capacity
was severely disrupted, as predicted due to the inability of the
mutated AR to bind DNA (Figure 3A). Strikingly, transgenic flies
expressing AR52Q A574D using GMR-GAL4 showed no degen-
erative phenotype even in the presence of DHT, indicating that
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Figure 3. DNA Binding by Polyglutamine-Expanded AR Is Required for Toxicity
(A) HEK293T cells were transfected with indicated AR constructs together with both the luciferase pARE-E1b-Luc and the b-galactosidase pCMVb reporter
constructs. AR transactivation was measured in the presence and absence of DHT by luciferase assay and normalized to b-galactosidase activity.
(B) Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and processed for immunocytochemistry.
AR was detected with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 mm.
(C) Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing DHT and adult eye phenotypes were assessed by light
microscopy.
(D) Blinded scoring of the external eye phenotypes in (C) using a quantitative scoring system.
(E) Third instar larvae expressing AR using the motor neuron driver D42-GAL4 were assessed for their ability to travel distances along the surface of an agar plate.
(F andG) Third instar larvae expressing AR in the salivary gland using fkh-GAL4were dissected and stainedwith DAPI (blue) and phalloidin (red). Overall gland size
is shown in (F), and cell size is shown in (G). Phalloidin staining was used to delineate cell boundaries and determine cell size. Scale bar, 50 mm.
**p < 0.01 in all panels. n.s., not significant. Bars, mean + SEM in all panels. See also Figures S2 and S3.
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expanded AR despite nuclear localization of AR and high trans-
gene expression (Figures 3B–3D, S2C, and S2D). Supporting this
result, flies expressing polyglutamine-expanded AR with the
A574D mutation showed no larval crawling defect when AR
was expressed in motor neurons (Figure 3E). Additionally, intro-
duction of the A574D mutation resulted in salivary gland cell size
that was indistinguishable from AR52Q without DHT (Figures 3F
and 3G). These results indicate that the native DNA-binding
function of AR is critical for pathogenesis.AF-2-Interacting Coregulators Modify the Toxicity
of Polyglutamine-Expanded AR
In the normal life cycle of AR, DNA binding is followed by the
recruitment of coregulators (either corepressors or coactivators)
that associate with AR at target promoters (Heinlein and Chang,
2002). We hypothesized that coregulator binding, an event
immediately downstream of DNA binding, might play a role in
pathogenesis.
In order to investigate the role of AR coregulators in SBMA, we
performed a candidate-based genetic screen for modifiers ofNeuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc. 941
Table 1. Results from RNAi-Based Targeted Genetic Screen
Hit from
Screen
Putative
AR Ortholog
Mechanism
of AR Interaction
AF-2-Based
Interaction
Validation by
Alternate Allele
Validation
by Larval Crawling Reference
CycD CCND1 CCND1 decreases
AR NTD/AF-2 interaction
X Df enhances enhances, p < 0.05 (Burd et al., 2005)
Dif RELA RELA competes for
AR coactivators
(Palvimo et al., 1996)
Dl RELA RELA competes for
AR coactivators
(Palvimo et al., 1996)
Ets96B ETV5 ETV5-AR interaction
represses metalloproteinase
expression
(Schneikert et al., 1996)
Fkh FOXH1 FOXH1 blocks DHT-induced
AR nuclear foci
(Chen et al., 2005)
Groucho AES AES interacts with basal
transcriptional machinery
(Yu et al., 2001)
gskt GSK3B GSK3B decreases
AR NTD/AF-2 interaction
X Df enhances enhances, p < 0.05 (Wang et al., 2004b)
Hey HEY1 HEY1 represses
AR AF-1
(Belandia et al., 2005)
Hr78 NR2C2 NR2C2 forms heterodimer
with AR
(Lee et al., 1999)
Usp NR2C2 NR2C2 forms heterodimer
with AR
(Lee et al., 1999)
jbug FLNA FLNA decreases
AR NTD/AF-2 interaction
X Df enhances enhances, p < 0.05 (Loy et al., 2003)
Lmpt FHL2 FHL2 increases
AR transactivation
in an AF-2-dependent
manner
X P-element enhances enhances, p < 0.01 (Mu¨ller et al., 2000)
Pat1 APPBP2 APPBP2 inhibits AR nuclear
translocation
(Zhang et al., 2004)
Pten PTEN PTEN inhibits AR nuclear
translocation, promotes
AR degradation
(Lin et al., 2004)
Rad9 RAD9 RAD9 decreases N/C
interaction, requires AF-2
X Df enhances lethal with AR52Q (Wang et al., 2004a)
Rbf RB1 RB1 increases
AR transactivation
(Yeh et al., 1998)
Smox SMAD3 SMAD3 interrupts
AR-coactivator interactions
(Hayes et al., 2001)
Smr NCOR1/2 NCOR1/2 decreases N/C
interaction, requires AF-2
X Df enhances n.s. (Liao et al., 2003)
wts LATS2 LATS2 decreases N/C
interaction, requires AF-2
X EMS mutation enhances enhances, p < 0.05 (Powzaniuk et al., 2004)
Seventy-three previously described AR coregulator genes were investigated for the existence of Drosophila orthologs. We identified 61 putative or-
thologs and obtained RNAi lines for these genes from the ViennaDrosophilaRNAi Center. RNAi lines were tested for their ability to modify the SBMA fly
phenotype. Shown are 19 hits from the screen that dominantly modified the AR52Q eye phenotype. Mammalian orthologs and mechanisms of AR
interaction are shown. As indicated, seven of these hits were found to have AF-2-based interactions. These seven hits were validated in motor neurons
by larval crawling assay, as well as with alternate alleles (classical alleles or aneuploid aberrations) in the eye. See also Figure S4.
Neuron
Native Functions of AR Mediate SBMA Pathogenesispolyglutamine-expanded AR toxicity. We began with 73 human
coregulators that are known to interact with AR. We identified
61 putativeDrosophila orthologs of these coregulators, including
23 coactivators, 34 corepressors, and 4 coregulators with dual
function. RNAi-mediated knockdown of 19/61 (31%) of these
Drosophila coregulators dominantly modified the SBMA fly942 Neuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc.phenotype (Table 1, Figures S4A and S4B). These modifiers
included some coregulators with obvious mechanisms of
enhancement, including Pat1 and Pten, which normally function
to inhibit AR nuclear translocation. The mechanism for other
modifiers was less clear, although there was an interesting
pattern among the hits because seven of them relate to the
Neuron
Native Functions of AR Mediate SBMA Pathogenesisfunction of the AF-2 domain of AR. Specifically, CycD, gskt, jbug,
Lmpt, Rad9, Smr, and wts (putative Drosophila orthologs of
CCND1, GSK3B, FLNA, four-and-a-half LIM domains 2 [FHL2],
RAD9, NCOR1/2, and LATS2, respectively) each play a role in
AF-2 interactions, either by binding AF-2 directly or by modifying
the AF-2-based interactionwith theNTD (Table 1). To confirm the
specificity of these hits and to rule out off-target effects due to
RNAi, we confirmed the effects of these AF-2-related hits in three
additional contexts. First, we confirmed that classical alleles and
aneuploid aberrations of these same genes would similarly
enhance the AR52Q eye phenotype (Figure S4C). Second, after
verifying that RNAi knockdown had no effect on larval crawling
ability when expressed in motor neurons in the absence of
AR52Q, we showed that these RNAi lines enhanced the AR52Q
larval crawling defect in 6/7 cases (Table 1, Figures S4D and
S4E). Third, we showed that the RNAi lines did not enhance
the AR52Q eye phenotype nonspecifically, by crossing RNAi-
expressing lines to an unrelated disease model of inclusion body
myopathy associated with Paget’s disease of bone and fronto-
temporal dementia (IBMPFD) that shows a modifiable degener-
ative eye phenotype (Ritson et al., 2010) (data not shown).
A Functional AF-2 Binding Site Is Required for Toxicity
AF-2 is a ligand-dependent hydrophobic surface flanked by
opposing charged residues, K720 and E897 (Figure 4A). This
surface is highly conserved across steroid hormone receptors
and across species, and in most cases serves as a binding
pocket for the LxxLL motifs of steroid receptor coactivator
(SRC) family members (He et al., 1999). Unlike other steroid
hormone receptors, however, the AF-2 of AR binds an additional
motif, defined as FxxLF, with higher affinity (Dubbink et al.,
2004; He et al., 2001, 2004). The FxxLF motif is found in a small
number of coregulators, as well as in the N terminus of AR, which
allows for an intra- or intermolecular interaction between the
NTD and AF-2 domains of AR. Current models propose that
AF-2 binds the NTD FxxLF motif when AR is mobile, and that
the NTD/AF-2 interaction is lost upon AR binding to DNA,
rendering AF-2 optimally accessible to coregulators (van Royen
et al., 2007).
Because our targeted RNAi screen highlighted the importance
of coregulator interactions with AF-2, we next investigated the
role of AF-2 function in polyglutamine-expanded AR toxicity by
taking advantage of three well-characterized mutations that
disrupt AF-2-based interactions without influencing protein
stability. The first, E897K, reverses the charge of one of the
two charge clamp residues in AF-2, thereby abolishing both
LxxLL- and FxxLF-mediated interactions (He et al., 1999)
(Figure 4A). The second, K720A, which neutralizes the charge
of the other charge clamp residue in AF-2, partially impairs
AF-2 function by severely disrupting LxxLL-mediated interac-
tions and decreasing FxxLF-based interactions by approxi-
mately 50% (Dubbink et al., 2004; He et al., 1999). The third,
G21E, located two amino acids from the FxxLF sequence in the
NTD, blocks the NTD/AF-2 interaction without affecting AF-2
structure (Callewaert et al., 2003). Neither E897K nor K720A
alters the equilibrium binding affinity for ligand (He et al., 1999).
In COS-1 cells, AR E897K, K720A, and G21E showed DHT-
induced nuclear translocation, similar to wild-type AR (FiguresS5A and S5B). Luciferase-based transactivation assays indi-
cated that while K720A and G21E mutants showed unaltered
transactivation capacity, the activity of AR E897K was modestly
decreased (Figure 4C). When expressed in vivo using fkh-GAL4,
we found that all three mutant proteins translocated to the
nucleus in response to DHT (Figure 4B). Importantly, the AF-2
mutations E897K and K720A strongly suppressed the pheno-
type caused by expression of polyglutamine-expanded AR in
salivary gland cells (Figures 4B, S5C, and S5D). In contrast, the
G21E mutation had no impact on salivary gland phenotype
(Figure 4B).
We next tested the toxicity of these mutant proteins using
GMR-GAL4. We found that introduction of the E897K mutation
abolished the degenerative eye phenotype, indicating that
complete disruption of AF-2 binding eliminates the toxicity of
polyglutamine-expanded AR despite high levels of AR expres-
sion (Figures 4E, S2C, S2D, and S5E). The K720A mutation
also suppressed degeneration, confirming that both LxxLL-
and FxxLF-based binding to AF-2 are critical mediators of
toxicity. In contrast, the G21E mutation had no discernable
impact on the eye phenotype. This latter result argues that
impaired coregulator interactions with AF-2, rather than impaired
NTD binding to AF-2, underlie the suppressive effect of E897K
and K720A mutations.
To corroborate the suppression seen by the K720A and E897K
mutations, we next used the driver elav-GAL4, which drives
transgene expression in all neurons. Whereas expressing
AR52Q with elav-GAL4 resulted in early larval lethality, intro-
ducing the AF-2mutations E897K or K720A resulted in increased
viability, as evidenced by more flies surviving to the pupal stage
(Figures 4D and S5F). When expressed in motor neurons with
D42-GAL4, the E897K and K720A mutations also significantly
suppressed the larval crawling defect seen in AR52Q flies
(Figure 4F). In addition, AF-2 mutations suppressed the NMJ
bouton phenotype, resulting in a significantly increased number
of synaptic boutons, whereas the G21E mutation had no effect
on this phenotype (Figures 4G and 4H). These results confirm
the suppression observed in the eye while extending the findings
to the cell type most affected in the human disease.
Expression Profile Analysis of AR Mutants Reveals
the Molecular Phenotype of Eye Degeneration
Though the rescue of eye degeneration we observe with muta-
tions to the DNA-binding domain or AF-2 domain is robust,
and we have corroborated the findings in other tissues, we felt
it would be valuable to generate a molecular phenotype to serve
as an objective, quantifiable assay of degeneration. Using
GMR-GAL4 to drive transgene expression in the eye, we used
Affymetrix arrays to profile gene expression changes in flies
expressing wild-type AR, polyglutamine-expanded AR, or poly-
glutamine-expanded AR with mutations affecting the DBD or
AF-2. One-hundred and forty-nine genes were identified whose
expression significantly changed in concert with ligand-induced
degeneration in AR52Q-expressing flies, representing a molec-
ular signature of degeneration (Figures 5A and S6, Table S1
available online). Hierarchical cluster analysis revealed strong
correlation between this molecular readout and visual inspection
of eye morphology (Figures 5A and 5B). Principal componentsNeuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc. 943
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Figure 4. Disruption of AF-2 Blocks Polyglutamine-Expanded AR Toxicity
(A) Crystal structure of the AR LBD (PDB ID: 2AMA) showing the AF-2 binding surface (gold) and the two charge clamp residues in AF-2, K720 (blue) and E897
(red). Green, FxxLF peptide cocrystallized with AF-2 (PDB ID: 1T7R). Pink, LxxLL peptide cocrystallized with AF-2 (PDB ID: 1T7F).
(B) Salivary glands of Drosophila larvae expressing AR using fkh-GAL4. Larvae were raised in medium containing DHT and processed for immunocytochemistry.
AR was detected with anti-AR antibody (green) and nuclei were stained with DAPI (blue). Scale bar, 50 mm.
(C) HEK293T cells were transfected with indicated AR constructs together with both the luciferase pARE-E1b-Luc and the b-galactosidase pCMVb reporter
constructs. AR transactivation was measured in the presence and absence of DHT by luciferase assay and normalized to b-galactosidase activity.
(D) Viability assay ofDrosophila expressing indicated AR transgenes using elav-GAL4. Crosses were performed inmedium containing DHT. The number of pupae
from each 131 cross was counted and normalized to lacZ. Expression of AR52Q resulted in larval lethality, whereas E897K or K720Amutations increased surviv-
ability to the pupal stage.
(E)Drosophila females expressing AR in eyes using GMR-GAL4 were raised in medium containing DHT and adult eye phenotypes were assessed by light micros-
copy. Left, AR constructs with 12Q. Right, AR constructs with expandedQ (AR52QWT, AR66Q E897K, AR72Q K720A, AR65QG21E). See Figure S5E for pheno-
type severity scores.
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Native Functions of AR Mediate SBMA Pathogenesisanalysis showed that introduction of the E897K and A574D
mutations reverted the molecular phenotype back to a pattern
that is indistinguishable from AR12Q or AR52Q without ligand
(Figure 5C). The K720Amutation partially reversed the molecular
phenotype observed in the AR52Q flies +DHT, reflecting the
milder suppression observed in these eyeswhen scored accord-
ing to the severity of their external degenerative phenotype.
For the purpose of our study, we used expression profiles as
a means of quantifying eye degeneration in our model. We
caution against making too much of the identity of the individual
genes whose expression is changed because the molecular
phenotype that accompanies eye degeneration is likely
dominated by secondary gene expression changes that are
a consequence rather than a cause of degeneration. Neverthe-
less, we recognized the possibility that embedded within these
expression profiles are some gene expression changes that
are primarily due to AR binding. To address this possibility, we
performed promoter analysis, which found no evidence of
enrichment of genes containing AR binding sites among the
DHT-responsive gene set (data not shown). Similarly, promoter
analysis showed no enrichment for genes that are responsive
to endogenous NHRs such as the ecdysone receptor (data not
shown). These results suggest that although the molecular
phenotype captured by our expression profiling can be used to
quantify neurodegeneration in the adult eye, secondary gene
changes are likely to obscure primary gene changes that
occurred in the first steps of pathogenesis.
In addition to corroborating our visual inspection with respect
to E897K, A574D, and K720Amutations and toxicity, the expres-
sion profile analysis also revealed that AR12Q +DHT caused
nearly the same molecular signature as AR52Q +DHT, although
the degree of expression level changes was generally weaker in
AR12Q compared with AR52Q (Figures 5A and S6). This obser-
vation is consistent with amodel in which amplification of normal
AR functionmay underlie the toxicity of polyglutamine-expanded
AR. Indeed, as described above, expression of AR12Q in fly eyes
can also result in degeneration when expressed at very high
levels.
Modification of the SBMA Phenotype by the FxxLF-
Containing Coregulator limpet Is Dependent on AF-2
The strong suppression observed in the E897K mutants (which
eliminates FxxLF-based interactions), along with the milder
suppression observed in the K720A mutants (which merely
decreases FxxLF-based interactions), implicated FxxLF-based
coregulator interactions as playing a significant role in toxicity.
Based on our genetic screen (Table 1), we further examined
the identity of our genetic modifiers in the context of FxxLF-
based AF-2 interactions. Although some of these modifiers are
not known to interact with AF-2 directly and not all contain FxxLF
motifs, the AR coregulator FHL2, the human ortholog of
Drosophila limpet, interacts with AF-2 directly via an FxxLF motif(F) Third instar larvae expressing AR using the motor neuron driver D42-GAL4 wer
(G andH) Larvae expressing AR using themotor neuron driver OK371-GAL4were
larvae, and stained using the postsynaptic marker discs large (DLG, green) and t
Scale bar, 10 mm.
**p < 0.01 in all panels. Bars, mean + SEM in all panels. See also Figures S2 and(Hsu et al., 2003). FHL2/limpet is well conserved between fly and
human (56.4% similarity, 74.4% identity), including the FxxLF
motif (Figure S7A), and is one of a family of LIM domain-contain-
ing proteins, several of which are known to play a role in motor
neuron development (Bhati et al., 2008). The exact mechanism
whereby FHL2modifies AR transactivation is unknown, although
LIM domain-containing proteins have been found to act as
bridging molecules between transcription factors, suggesting
that they may act as scaffolds in the assembly of transcriptional
complexes (Wadman et al., 1997). Thus, limpet provided a good
candidate for further investigation, given that it may act to posi-
tively or negatively regulate the assembly of AF-2 complexes.
We therefore performed epistasis experiments to examine the
ability of limpet tomodify the toxicity of polyglutamine-expanded
AR. Though RNAi knockdown of limpet in the Drosophila eye
using GMR-GAL4 results in no externally visible phenotype in
flies without the mutant AR transgene, limpet knockdown in flies
expressing AR52Q enhanced the AR52Q degenerative eye
phenotype (Figures 6A, 6C, 6M, S7B, and S7C). Similarly, a clas-
sical P-element allele (LmptGE27535) of limpet enhanced the
AR52Q phenotype (Figures 6B, 6C, 6M, and S7B). A chromo-
somal duplication that produces two copies of the limpet gene
(Dp(3;3)st+g18) (Tearle et al., 1989) suppressed the AR52Q
phenotype, suggesting that depletion of limpet by AR contrib-
utes to toxicity (Figures 6C, 6D, 6M, and S7B). This suppression
was confirmed through expression profile analysis in which we
determined that 46% of the gene expression changes that
accompanied ligand-dependent degeneration in AR52Q flies
were completely reversed by limpet duplication (Figure 6N).
Interestingly, although genetic manipulation of limpet did not
modify the mild phenotype of flies expressing AR12Q at
moderate levels (data not shown), limpet alleles did modify the
more severe phenotype of flies expressing AR12Q at very high
levels (Figures 6E–6H and 6M), suggesting that the molecular
pathophysiology of high-expressing AR12Q flies is related to
that of AR52Q flies. Importantly, limpet knockdown did not
modify the phenotype of AR66Q E897K, indicating that the
enhancement by limpet RNAi requires a functional AF-2 binding
surface (Figures 6I and 6J). In addition, limpet duplication did not
suppress the degenerative phenotype caused by pure polyglut-
amine protein (127Q) (Kazemi-Esfarjani and Benzer, 2000),
demonstrating that increased levels of limpet are not globally
protective, but instead show a specific genetic interaction with
AR (Figures 6K and 6L). These results are consistent with amodel
in which polyglutamine-expanded AR causes toxicity through
AF-2-based interactions with coregulators.
DISCUSSION
In this study, we investigated the basis for the toxicity of polyglut-
amine-expanded AR by systematically interrogating ligand-
dependent modifications of this NHR. We showed that nucleare assessed for their ability to travel distances along the surface of an agar plate.
raised inmedium containing vehicle or DHT, dissected as third instar wandering
he presynaptic marker HRP (red). Type 1B boutons were counted at muscle 4.
S5.
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Figure 5. Molecular Phenotype of AR Mutants
(A) RNA from fly heads expressing AR using GMR-GAL4 was extracted and analyzed using Affymetrix arrays. Using a false discovery rate of 0.1, 149 genes were
identified as showing significant changes in AR52Q flies due to DHT treatment and were thereby selected for further analysis.
(B) Scoring of the external eye phenotype shows a correlation between the severity of the observable external phenotype and the clustering results.
(C) PCA analysis using the 149 genes shown in (A).
See also Figure S6 and Table S1.
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Native Functions of AR Mediate SBMA Pathogenesistranslocation of polyglutamine-expanded AR is necessary, but
not sufficient, for toxicity and that DNA binding is required for
toxicity. Insight from a genetic screen indicated that native inter-
actions, those mediated by the AF-2 domain in particular, play
a key role in toxicity. This suspicion was confirmed by our results946 Neuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc.indicating that toxicity is dependent upon a functional AF-2
binding surface. Specifically, we demonstrated that K720A and
E897K mutations to the AF-2 coregulator interaction surface
attenuated polyglutamine-expanded AR toxicity, whereas inter-
ruption of the NTD/AF-2 interaction had no effect. In the majority
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Figure 6. Manipulation of limpet Levels Modifies Polyglutamine-Expanded AR Toxicity in an AF-2-Dependent Manner
(A–D) RNAi knockdown of limpet (A) and a P-element allele of limpet (LmptGE27535) (B) enhances the phenotype of AR52Q alone (C). Flies with a chromosomal
duplication of a region containing limpet (Dp(3;3)st+g18) (D) show suppression of the AR52Q degenerative phenotype.
(E–H) Limpet alleles similarly modify the phenotype of AR12Q flies with a strong phenotype.
(I–J) Expression of limpet RNAi fails to enhance the phenotype in flies expressing AR66Q E897K.
(K and L) Chromosomal duplication of limpet fails to suppress the phenotype in flies expressing pure polyglutamine (127Q).
(M) Blinded scoring of the external eye phenotypes in (A)–(H) using a quantitative scoring system. All crosses performed onmedium containing DHT. Bars, mean +
SEM. **p < 0.01, *p < 0.05.
(N) Of 81 genes that changed in a DHT-dependent manner by expression profile analysis, 37 genes showed an opposite change in the presence of limpet dupli-
cation. Expression changes of these 37 genes are shown and plotted as relative expression (SD) to the mean.
See also Figure S7.
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Native Functions of AR Mediate SBMA Pathogenesisof assays, the E897Kmutation resulted in a stronger suppression
than K720A (Figures 4D, 4E, 4G, and 4H), an observation that is
consistent with the stronger AF-2 disruption due to the reversal
of charge (E/K) compared to the neutralization of charge (K/A).
These results indicate that AF-2 function is essential for polyglut-
amine-expanded AR toxicity. Importantly, the morphological
(Figure 1J) and molecular (Figure 5) phenotypes of AR12Q reca-
pitulate those of AR52Q, only less strongly, suggesting that poly-glutamine-expanded AR toxicity may be mediated by amplifica-
tion of wild-type AR function. We conclude that SBMA
pathogenesis is mediated by amplification of native AR interac-
tions, and that functions of the AF-2 domain are essential to
toxicity.
Although we have demonstrated that polyglutamine-
expanded AR toxicity requires DNA binding followed by associa-
tion with AF-2 coregulators, we do not yet know how this resultsNeuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc. 947
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Figure 7. Schematic Representation of the
Minimal Ligand-Dependent Events that
Precede Initiation of Pathogenesis
(1) Ligand binding induces a conformational
change in the LBD to create the AF-2 binding
surface. Ligand also induces posttranslational
modifications that are not depicted. (2) Ligand-
activated AR translocates to the nucleus. (3) Prior
to DNA binding, the AF-2 domain is occupied by
the N-terminal FxxLF in an intramolecular or inter-
molecular interaction. (4) Following DNA binding,
AF-1 and AF-2 interact with coregulators. In order
to initiate pathogenesis, polyglutamine-expanded
AR must bind DHT, translocate to the nucleus,
bind DNA, and interact with coregulators at AF-2.
Whereas interactions at AF-1 modify toxicity,
AF-2 function is essential for toxicity.
Neuron
Native Functions of AR Mediate SBMA Pathogenesisin toxicity. We favor a model in which the AF-2 domain of AR
competes with other transcription factors for a finite supply of
coregulators. According to thismodel, amplificationofARactivity
could result in reduced availability of coregulators for important
functions. This model is consistent with our observation that
RNAi-mediated knockdown of AF-2 interactors consistently
enhances toxicity. A key outstanding question not answered in
this study is how AR activity in the nucleus is amplified. One
possibility is that aggregation-prone polyglutamine-expanded
AR adopts a toxic conformation that amplifies AF-2-based inter-
actions. However, the fact that we did not detect polyglutamine
length-dependent changes in coimmunoprecipitation of AR and
FHL2 argues against this possibility (Figure S8). An alternative
possibility is that polyglutamine expansion amplifies AR activity
(and AF-2 function in particular) independent of any change in
the intrinsic ability of AR to interact with coregulators—for
example, by reducing the inactivation rate of DNA-bound AR or
by reducing the rate of AR nuclear efflux, similar to what has
been observed for ataxin-7 (Taylor et al., 2006). The mechanism
by which polyglutamine expansion amplifies AR nuclear activity
will be an important focus for future studies. In previous analysis
we observed the presence of high molecular weight species of
presumed aggregated polyglutamine-expanded AR in our
Drosophilamodel of SBMA (Pandey et al., 2007). These species
are also present in themutant forms of AR included in the current
study. Quantitative analysis shows no correlation between the
amount of highmolecular weight species and neurodegeneration
in thisDrosophilamodel (Figures S2E and S2F). While this obser-
vation is intriguing, thorough assessment of the relative contribu-
tions of aggregation and altered native function will require
follow-up studies in mammals.
Though our results indicate that AF-2 function is essential to
toxicity (Figure 7), it is likely that multiple native interactions influ-
ence the toxicity of polyglutamine-expanded AR, and this is948 Neuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc.substantiated by the results of our genetic
screen. For example, AF-1-interacting
coregulators Hey and Rbf were found to
modify toxicity, indicating that coregula-
tor interactions at AF-1 likely participate
in pathogenesis. One of these proteins,Rbf, was also recently shown to modulate the toxicity of poly-
glutamine-expanded AR in another Drosophila model of
SBMA. In this study, Rb was shown to have increased associa-
tion with polyglutamine-expanded AR, leading to reduced Rb
activity and subsequent loss of regulation of Rb-associated
genes (Suzuki et al., 2009). Such a model may also apply to
AF-2-based interactions.
These observations may easily be aligned with recent reports
relating to three other polyglutamine diseases in which the data
point away from the intrinsic toxicity of expanded polyglutamine
and toward the toxic consequences of amplified native interac-
tions. A series of publications from the Orr and Zoghbi labs has
illuminated the role of native interactions of ataxin-1 in the path-
ogenesis of SCA1 (Emamian et al., 2003; Lim et al., 2008; Tsuda
et al., 2005). Specifically, polyglutamine expansion favors inter-
action with the RNA-binding protein RBM17, contributing to
SCA1 neuropathology through a gain-of-function mechanism.
Concomitantly, polyglutamine expansion attenuates interaction
with Capicua, contributing to SCA1 through a partial loss-of-
function mechanism (Lim et al., 2008). Analogous mechanisms
have been implicated in the pathogenesis of SCA7 and SCA17,
although less is known about the identity of the native interac-
tions that are key to pathogenesis (Friedman et al., 2007; Helm-
linger et al., 2006; McMahon et al., 2005; Palhan et al., 2005).
Though the AF-2 result is interesting insofar as it highlights
a model in which polyglutamine expansion drives toxicity
through native function, the greatest significance is that these
results reveal an opportunity for therapeutic intervention. An
entire therapeutic enterprise has developed around targeting
AF-2/coregulator interactions with small molecules in efforts to
combat prostate cancer, hyperandrogenic syndromes, and
male-pattern baldness, among others (Chang and McDonnell,
2005; Schapira, 2002). Indeed, the drug ASC-J9 was found to
ameliorate neurodegeneration in a mouse model of SBMA and
Neuron
Native Functions of AR Mediate SBMA Pathogenesisthis was attributed to increased degradation of polyglutamine-
expanded AR (Yang et al., 2007). However, in light of our findings
it is worth noting that ASC-J9 disrupts the interaction between
AF-2 and FxxLF-containing coregulators, suggesting that the
beneficial effect of ASC-J9 may represent targeted interruption
of AF-2-based interactions that are essential mediators of
toxicity (Ohtsu et al., 2002). Although further studies are required
to replicate these results in amammalianmodel, our current find-
ings allow for the possibility that SBMA patients will not have to
rely on drugs that result in global androgen deprivation, but
instead hope for therapeutic agents that will act inmotor neurons
to specifically target toxic AR interactions.
EXPERIMENTAL PROCEDURES
Antibodies
Primary antibodies used were as follows: AR (N20, Santa Cruz Biotechnology),
actin (I-19-R, Santa Cruz Biotechnology), a-tubulin (T5168, Sigma), FLAG (M2
F1804, Sigma), Anti-HRP-Cy3 conjugate (Jackson Immunoresearch), and
Discs-Large (DSHB 4F3). Secondary antibodies used for biochemistry were
as follows: IRDye 800CW goat anti-mouse IgG, IRDye 680 goat anti-mouse
IgG, IRDye 680 goat anti-rabbit IgG, and IRDye 800CW goat anti-rabbit IgG
(Li-Cor Biosciences). For in vivo staining, goat anti-mouse Alexa Fluor 488
(Invitrogen), goat anti-rabbit Alexa Fluor 488 (Invitrogen), and FITC anti-rabbit
(Jackson ImmunoResearch) were used. The mouse anti-Discs-Large
hybridoma antibody developed by Corey Goodman was obtained from the
Developmental Studies Hybridoma Bank developed under the auspices of
the NICHD and maintained by the University of Iowa, Department of Biology,
Iowa City, IA 52242.
Cloning
Mutagenesis (G21E, S210D, A574D, K720A, S790D, and E879K) was per-
formed using Quikchange II XL Mutagenesis Kit (Stratagene). NLS sequences
were added to AR using a PCR-based method.
Eye Disc Staining
UAS-AR flies were crossed to GMR-GAL4 flies on food with or without 1 mM
DHT (Steraloids). Pupal eye discs were dissected and fixed with 4% PFA for
30 min at room temperature. Discs were stained with primary antibody for
16 hr at 4C and secondary antibody for 1 hr at room temperature. Phalloidin
staining (Alexa Fluor 568 Phalloidin, Invitrogen) was performed for 2 hr at room
temperature. Discs were washed and embedded using Glycergel (Dako),
mounted, and examined by laser scanning confocal microscopy.
Eye Phenotypes
UAS-AR flies were crossed to GMR-GAL4 flies at 25C or 29C on food con-
taining either 1 mM DHT (Steraloids) or 1% ethanol. Eye phenotypes of anes-
thetized female flies were evaluated with a Leica MZ APO or M205C stereomi-
croscope and photographed with a Leica DFC320 digital camera. Blinded
scoring of the AR phenotype was performed as previously described (Pandey
et al., 2007).
Fly Stocks
Mutant AR flies were generated by cloning human AR constructs into pUAST.
DNA was injected into w1118 embryos by BestGene Inc. (Chino Hills, CA). At
least four independently generated transgenic lines were evaluated for all
AR-expressing flies. Classical alleles and deficiency lines [Df(1)sd72b, Df(3R)
tll-e, Df(2R)Exel6079, Df(3L)Cat, Df(1)N105, wts[3-17], LmptGE27535, and Dp
(3;3)st+g18] were obtained from Bloomington Stock Center (Bloomington,
IN). RNAi transgenic lines were obtained from the Vienna Drosophila RNAi
Center (Vienna, Austria).
Larval Crawling
UAS-AR flies were crossed to D42-GAL4 flies at 25Con food containing either
1 mM DHT (Steraloids) or 1% ethanol. Larval crawling was performed on a 1%agarose gel in a 245 mm2 dish with gridlines spaced by 2.5 mm. Wandering
third instar larvae were allowed to acclimate for 5 min, and the number of grid-
lines passed by the posterior end of the larvae in 30 s was counted. Each larva
was tested three times.
Luciferase Assays
Luciferase assays were performed in HEK293T cells as previously described
(Palazzolo et al., 2007). Briefly, cells were transfected with indicated AR
constructs together with both the luciferase pARE-E1b-Luc and the b-galacto-
sidase pCMVb reporter constructs. AR transactivation was measured in the
presence and absence of DHT by luciferase assay and normalized to b-galac-
tosidase activity.
Microarray Gene Expression Profiling Analysis
UAS-AR flies were crossed to GMR-GAL4 flies at 29C on food containing
either 1 mM DHT (Steraloids) or 1% ethanol. Heads of 15 female offspring
were collected and frozen, and RNA was extracted using TRIzol (Invitrogen).
Details of processing and analysis may be found in Supplemental Information.
Neuromuscular Bouton Counting
UAS-AR flies were crossed to OK371-GAL4 flies at 25C on food containing
either 1 mM DHT (Steraloids) or 1% ethanol. Third instar larvae were heat
killed, dissected in PBS, and fixed with 4% PFA for 20 min. Primary antibody
staining was performed at 4C overnight and secondary antibody staining was
performed at room temperature for 4 hr. After staining, pelts were mounted in
Fluoromount-G (SouthernBiotech). Boutons at muscle 4 segments A2–A5 on
the right and left side were quantified in the mounted muscle preparations.
RNAi Screen
The list of 73 AR-interacting coregulators was generated through literature
review. Orthology prediction for Drosophila orthologs of these coregulators
was performed using the HUGO Gene Nomenclature Committee Comparison
of Orthology Prediction tool along with PSI-BLAST. RNAi lines were obtained
from the Vienna Drosophila RNAi Center. Flies expressing UAS-RNAi were
crossed to flies expressing GMR-GAL4; UAS-AR52Q at 29C on food
containing either 1 mM DHT (Steraloids) or 1% ethanol. Eye phenotypes of
anesthetized female flies were evaluated with a Leica MZ APO or M205C
stereomicroscope and photographed with a Leica DFC320 digital camera.
Salivary Gland Staining
UAS-AR flies were crossed to fkh-GAL4 flies at 25C on food containing either
1 mM DHT (Steraloids) or 1% ethanol. For antibody staining, wandering third
instar larvae were collected and salivary glands were dissected into 4% PFA
in PBS. Glands were stained with primary antibody for 16 hr at 4C and
secondary antibody for 2 hr at room temperature. For details of fixation and
washing, see Supplemental Information. For phalloidin staining, wandering
third instar larvae were collected and salivary glands were dissected and
stained as previously described (Martin and Baehrecke, 2004) using Texas
red phalloidin (Invitrogen). Slides were examined using a Leica DMIRE2micro-
scope and cell size was determined using phalloidin staining and Slidebook
software (Intelligent Imaging Innovations).
Statistics
Statistical comparisons were performed by ANOVA and Tukey HSD Test or
Student’s t test as appropriate.
Viability
UAS-AR flies were crossed to elav-GAL4 flies at 25Con food containing either
1 mM DHT (Steraloids) or 1% ethanol. Crosses were set up using one female
and one male. The number of pupae on the sides of the vial and the surface of
the food were counted 16 days after parents were added.
Western Blotting
UAS-AR flies were crossed to GMR-GAL4 flies at 29C. Heads of three female
offspring were collected, frozen, and lysed in RIPA buffer (150mMNaCl, 6 mM
Na2HPO4, 4 mM NaH2PO4, 2 mM EDTA, 1% NaDOC, 1% Triton X-100, and
0.1% SDS) with protease inhibitors (Roche). The lysate was sonicated, boiled,Neuron 67, 936–952, September 23, 2010 ª2010 Elsevier Inc. 949
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Native Functions of AR Mediate SBMA Pathogenesisand run on 7.5%Tris-HCl SDS-PAGE gels (Bio-Rad). Proteinswere transferred
to nitrocellulose membranes (GE Healthcare) and immunoblotted. Blots were
developed using the Odyssey Imaging System (Li-Cor Biosciences).
SUPPLEMENTAL INFORMATION
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